Advanced search
Publication Cover
Expert Opinion on Orphan Drugs Volume 4, 2016 - Issue 2
Submit an article Journal homepage
51
Views
8
CrossRef citations to date
0
Altmetric
Review

Prospects and progress of oncolytic viruses for treating peripheral nerve sheath tumors

Slawomir AntoszczykMolecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA;Department of Neurosurgery, Harvard Medical School, Boston, MA, USA
&
Samuel D. RabkinMolecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA;Department of Neurosurgery, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
Pages 129-138 | Received 25 Sep 2015, Accepted 02 Dec 2015, Published online: 26 Dec 2015

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333–340.
  • July J, Guha A. Peripheral nerve tumors. Handb Clin Neurol. 2012;105:665–674.
  • Porter DE, Prasad V, Foster L, et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;756395(10):7.
  • LaFemina J, Qin LX, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20(1):66–72.
  • Lin AL, Gutmann DH. Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol. 2013;10(11):616–624.
  • Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone: WHO classification of tumours. 4th ed. Geneva: WHO Press; 2013.
  • Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670.
  • Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008;1785(2):217–231.
  • Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295–300.
  • Lichty BD, Breitbach CJ, Stojdl DF, et al. Going viral with cancer immunotherapy. Nature Rev Cancer. 2014;14(8):559–567.
  • Angarita FA, Acuna SA, Ottolino-Perry K, et al. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. Trends Mol Med. 2013;19(6):378–392.
  • Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12(2):141–161.
  • Kaur B, Cripe TP, Chiocca EA. “Buy one get one free”: armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther. 2009;9(5):341–355.
  • Jeyaretna DS, Kuroda T. Recent advances in the development of oncolytic HSV-1 vectors: ‘arming’ of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Curr Opin Mol Ther. 2007;9(5):447–466.
  • Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe. 2014;15(3):260–265.
  • Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005;12(5):437–445.

• The only clinical trial so far reporting OV treatment of PNST.

  • Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2015. DOI:10.1007/s40265-015-0522-7.
  • Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced Melanoma. J Clin Oncol. 2015;33(25):2780–2788.
  • Messerli SM, Prabhakar S, Tang Y, et al. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006;17(1):20–30.

• Use of novel schwannoma models to demonstrate therapeutic efficacy of oHSV in benign PNST.

  • Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007;14(5):460–467.
  • Antoszczyk S, Spyra M, Mautner VF, et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014;16(8):1057–1066.

•• Development of new orthotopic MPNST models and demonstration of oHSV efficacy in both human MPNST stem-like cells and in mouse immunocompetent tumors. First description of immunotherapeutic strategy to treat MPNST.

  • Liu TC, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006;14(6):789–797.

•• First description of use of OV armed with therapeutic transgene to treat MPNST, targeting both the tumor cells and vasculature.

  • Mahller YY, Rangwala F, Ratner N, et al. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer. 2006;46(7):745–754.
  • Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 2007;15(2):279–286.
  • Gil Z, Rein A, Brader P, et al. Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin Cancer Res. 2007;13(21):6479–6485.

• First description of OV to safely treat carcinoma PNI.

  • Kelly K, Brader P, Rein A, et al. Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function. FASEB J. 2008;22(6):1839–1848.
  • Mahller YY, Vaikunth SS, Ripberger MC, et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 2008;68(4):1170–1179.
  • Maldonado AR, Klanke C, Jegga AG, et al. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med. 2010;12(7):613–623.

• Description of transcriptionally targeted OV strategy for selective growth in MPNST.

  • Liu TC, Zhang T, Fukuhara H, et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006;12(22):6791–6799.
  • Siurala M, Bramante S, Vassilev L, et al. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer. 2015;136(4):945–954.
  • Deyle DR, Escobar DZ, Peng KW, et al. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Gene. 2015;565(1):140–145.

•• First description of use of MV to treat MPNST and demonstration of the utility of noninvasive imaging with NIS to follow virus spread in MPNST.

  • Paglino JC, van den Pol AN. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol. 2011;85(18):9346–9358.
  • Hilton DA, Hanemann CO. Schwannomas and their pathogenesis. Brain Pathol. 2014;24(3):205–220.
  • Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol. 2013;115:957–967.
  • Sughrue ME, Yeung AH, Rutkowski MJ, et al. Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg. 2011;114(2):359–366.
  • Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 1997;151(6):1649–1654.
  • Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135–1143.
  • Karajannis MA, Ferner RE. Neurofibromatosis-related tumors: emerging biology and therapies. Curr Opin Pediatr. 2015;27(1):26–33.
  • Rodriguez FJ, Folpe AL, Giannini C, et al. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123(3):295–319.
  • Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939–955.
  • Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nature Rev Cancer. 2015;15(5):290–301.
  • Pizem J, Nicholson KM, Mraz J, et al. Melanocytic differentiation is present in a significant proportion of nonpigmented diffuse neurofibromas: a potential diagnostic pitfall. Am J Surg Pathol. 2013;37(8):1182–1191.
  • Jett K, Nguyen R, Arman D, et al. Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1. Am J Med Genet A. 2015;167(7):1518–1524.
  • Khosrotehrani K, Bastuji-Garin S, Riccardi VM, et al. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients. Am J Med Genet A. 2005;132A(1):49–53.
  • Brems H, Beert E, de Ravel T, et al. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10(5):508–515.
  • Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–2021.
  • Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11(4):322–328.
  • Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13(12):1218–1224.
  • Thway K, Fisher C. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 2014;18(2):109–116.
  • Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol. 2007;82(2):187–192.
  • Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(2):135–147.
  • Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 2008;29(1):74–82.
  • Endo M, Yamamoto H, Setsu N, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19(2):450–461.
  • Grobmyer SR, Reith JD, Shahlaee A, et al. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97(4):340–349.
  • Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–885.
  • Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–3391.
  • Marchesi F, Piemonti L, Mantovani A, et al. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 2010;21(1):77–82.
  • Roh J, Muelleman T, Tawfik O, et al. Perineural growth in head and neck squamous cell carcinoma: a review. Oral Oncol. 2015;51(1):16–23.
  • Bapat AA, Hostetter G, Von Hoff DD, et al. Perineural invasion and associated pain in pancreatic cancer. Nature Rev Cancer. 2011;11(10):695–707.
  • Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia, PA: Lippincott Williams &Wilkins; 2013. p. 1823–1897.
  • Jackson JD, McMorris AM, Roth JC, et al. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther. 2014;21(11):984–990.
  • Peters C, Rabkin SD. Designing herpes viruses as oncolytics. Mol Ther Oncolytics. 2015;2:15010.
  • Lee CH, Chung CK, Hyun SJ, et al. A longitudinal study to assess the volumetric growth rate of spinal intradural extramedullary tumour diagnosed with schwannoma by magnetic resonance imaging. Eur Spine J. 2015;24(10):2126–2132.
  • Farassati F, Pan W, Yamoutpour F, et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol. 2008;173(6):1861–1872.
  • Spyra M, Kluwe L, Hagel C, et al. Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One. 2011;6(6):e21099.
  • Mashour GA, Moulding HD, Chahlavi A, et al. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001;169(1):64–71.
  • Geevarghese SK, Geller DA, de Haan HA, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010;21(9):1119–1128.
  • Kanai R, Rabkin SD. Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol. 2013;2(2):129–142.
  • Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193–201.
  • Kanai R, Wakimoto H, Cheema T, et al. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010;6(4):619–634.
  • Wildy P. The progression of herpes simplex virus to the central nervous system of the mouse. J Hyg. 1967;65(2):173–192.
  • Townsend JJ, Collins PK. Peripheral nervous system demyelination with herpes simplex virus. J Neuropathol Exp Neurol. 1986;45(4):419–425.
  • Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther. 2001;1(3):525–538.
  • Blackford AN, Grand RJ. Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol. 2009;83(9):4000–4012.
  • Larson C, Oronsky B, Scicinski J, et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6(24):19976–19989.
  • Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18(10):1874–1884.
  • Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol. 2009;330:213–241.
  • Msaouel P, Opyrchal M, Domingo Musibay E, et al. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther. 2013;13(4):483–502.
  • Griffin DE. Measles virus and the nervous system. Handb Clin Neurol. 2014;123:577–590.
  • Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012;93(Pt 12):2529–2545.
  • Wollmann G, Tattersall P, van den Pol AN. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol. 2005;79(10):6005–6022.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.